Marico

Well-oiled for growth in medium term

Marico's 3QFY25 results were broadly in line with our estimates, driven by betterthan-expected operating profits. Domestic volume growth of 6% was ahead of our expectations of 4-5% owing to solid offtake in foods and digital first brands. Moreover, continued momentum in international business was the cherry on the cake. Domestic business was also supported by the following factors: a) Parachute's volume grew 3% YoY, aided by market share gains and accelerated conversion from loose to branded products, as historically seen in an inflationary copra environment; b) Saffola reported low single digit volume growth and 24% revenue growth on the back of 15% price hike taken in 2Q; c) the Foods business reported 31% growth, supported by steady growth in the Saffola oats franchise and significant scale-up in new products (Plix and True Elements); and d) Premium personal care saw strong growth, driven by digital-first brands. However, valueadded hair oil declined 2% due to increased competitive headwinds in the BOP segment, though mid and premium sub-segments continued to perform well. The international business maintained its double-digit constant currency growth momentum, with each key market delivering broad-based growth.

- 3QFY25 results summary: Marico's 3QFY25 results were broadly in line with our estimates. The consolidated gross margin contracted c180 bps YoY to 49.5%, owing to inflationary pressure in the domestic business (GM down 250 bps YoY) due to a steep increase in copra prices (up 38% YoY) and rice bran oil (up 19%). To an extent, it was compensated via strong performance in the international business (EBIT margin increased 120 bps YoY) and reduced losses in digital-first brands. The EBITDA margin contracted 210 bps to 19.1% YoY due to higher operating overheads and advertising costs (both were up 19% YoY). Adjusted PAT grew 4% YoY (NPM contracted 150 bps to 14.3%).
- Outlook and valuation: We maintain Marico as a BUY with a target price of INR 735 (46x FY27 EPS, a 12% premium to its 5-year average PE), given the expected revenue/EBITDA/PAT CAGRs of 10%/11%/11% over FY24-27. This outlook is supported by 1) the strong performance of the domestic business: (a) Parachute (35% of domestic sales) is expected to achieve mid-single-digit volume growth driven by market share gains and a shift from unbranded to branded products, particularly in an inflationary copra environment. Additionally, we expect double-digit revenue growth to continue even in FY26; (b) Saffola edible oil (20% of domestic sales) is projected to see double-digit revenue growth following a 15% price increase toward the end of 2Q; and (c) VAHO's easing competitive intensity in the BOP segment and an uptick in the mid-to-premium segment are expected to drive improved results; 2) Significant improvement in the profitability of the fast-growing foods and digital-first business (20% of domestic sales); and 3) sustained double-digit constant currency revenue growth momentum in the international business as the currency headwinds subside. However, in 2HFY25, the operating margin will likely remain under pressure for the next 2-3 quarters due to higher raw material costs, particularly for copra and the edible oil basket. Kindly note that we have reduced our valuation multiple from 50x to 46x to account for the urban slowdown and the overall correction in consumer sector multiples.

Quarterly/annual financial summary

(INR mn)	3QFY25E	3QFY24	YoY (%)	2QFY25	QoQ (%)	FY24	FY25E	FY26E	FY27E
Net Sales	27,211	24,220	12.4	26,640	2.1	96,530	1,05,833	1,16,563	1,27,316
EBITDA	5,315	5,130	3.6	5,220	1.8	20,260	21,790	24,701	27,583
APAT	4,002	3,830	4.5	3,880	3.2	14,810	15,819	18,013	20,197
Diluted EPS (Rs)	3.1	3.0	4.5	3.0	3.2	11.5	12.2	13.9	15.6
P/E (x)						55.8	52.3	45.9	40.9
EV/EBITDA (x)						40.4	37.3	32.8	29.2
Core RoCE (%)						56.1	54.4	64.8	72.6
<u> </u>	LICIE	n 1							

Source: Company, HSIE Research



BUY

CMP (as on 3	INR 671		
Target Price	INR 735		
NIFTY	23,508		
KEY CHANGES	OLD	NEW	
Rating	BUY	BUY	
Price Target	INR 760	INR 735	
EPS %	FY25E	FY26E	
EF3 %	0.3%	-0.1%	

KEY STOCK DATA

Bloomberg code	MRC	O IN
No. of Shares (mn)		1,295
MCap (INR bn) / (\$ mn)	869/10	0,028
6m avg traded value (INR r	nn) í	1,576
52 Week high / low	INR 720)/486

STOCK PERFORMANCE (%)

	3M	6M	12M
Absolute (%)	4.8	(0.5)	27.1
Relative (%)	7.2	4.7	19.0

SHAREHOLDING PATTERN (%)

	Sep-24	Dec-24
Promoters	59.20	59.11
FIs & Local MFs	11.21	12.86
FPIs	24.87	23.36
Public & Others	4.61	4.60
Pledged Shares	0.08	0.08
Source : BSE		

Pledged shares as % of total shares

Vishal Gutka vishal.gutka@hdfcsec.com +91-22-6171-7324

Anuj D anuj.d@hdfcsec.com +91-22-6171-7357



3QFY25 Con call Takeaways

Domestic Business (74% of revenue, 69% of EBIT)

Parachute (35% of domestic revenue):

- Parachute volume growth was around 3%, despite the company absorbing the 1% volume hit owing ml reduction in one of the key price point pack (instead of taking price increase). Additionally, secondary volume offtakes grew in high single digits owing to market share gains.
- Parachute recorded 15% revenue growth, aided via pricing interventions made over the past 9 months. Over and above this price increase, the company implemented another round of price increases toward the end of 3Q (5%) due to continued inflation in copra prices (up 55% YoY).
- The brand continued to gain market share (+140 bps on a MAT basis) due to accelerated conversion from loose to branded products in an inflationary copra environment.
- Management stated that they intend to pass on benefits of reduced copra price, as and when required in order to retain consumer franchisee

Value Added Hair Oils (20% of domestic revenue):

- Declined 2% in value terms due to competitive headwinds and persistent sluggishness in the bottom-of-the-pyramid (BOP) segment. However, the management mentioned that they are witnessing definitive signs of recovery on a sequential basis.
- Most brands in this category have significantly reduced ad spends and are diverting their ATL budgets toward trade promotions, impacting revenue growth at the category level.
- The mid and premium segments fared better in comparison, gaining 70 bps in market share.
- Management stated it does not intend to engage in a "price war" in the value-formoney segment but will focus on gaining market share in the mid-to-premium segments, where it has a better opportunity for success. Roughly 15-18 months ago, most national value-added hair oil companies turned to shrinkflation (reducing grammage) to combat RM inflation challenges. However, BOP customers expect certain usage frequencies when purchasing LUPs of VAHO brands, leading some to shift to regional brands or national brands that avoid significant shrinkflation.
- Management believes the segment has bottomed out and expects gradually improving trends ahead due to (a) increased share of mid-to-premium segments, (b) shrinkflation coming into the base from 2HFY25, and (c) visible ATL investments and brand activation.

Saffola Edible Oils (18% of domestic revenue):

- Volume growth came in at low single digit, while pricing growth was positive. Marico implemented a 15% price increase to counter the sharp hike in import duties on edible oil, Saffola reported 24% revenue growth for 3QFY25.
- The "Step-Up for Your Heart" campaign on World Heart Day improved visibility, reaching 26 mn. people across 15 cities.

Foods Business (10% of domestic revenue):

 The Foods business reported 31% growth, nearing INR 10 bn in ARR, driven by double digit growth in Saffola oats and the scaling up of relatively new franchises (Plix and True Elements). Oats / Masala oats continues to grow in strong double digit, driven under penetrated nature of the category

- Launched Saffola Masala Millets during 2Q; a savoury option for consumers shifting toward healthier eating habits, available in two flavours (Masala Delight and Tomato Delight) at INR 20.
- Honey and soya chunks are the largest subcategories within the food segment after oats. However, Marico does not plan a major scale-up of soya chunks due to historically low margins and will only scale up this sub-segment if it identifies a niche within it. Moreover, Honey has done well in organized trade, but yet to pickup in GT
- Marico is prototyping Muesli and snacking segments and depending upon execution, management thinks of scaling up this sub category
- Management intends to be aggressive in quick commerce in the food category, leveraging the impulse-buy nature of the products.
- The food category is skewed toward the OT channel and will benefit from expansion into Marico's strong GT network.

Premium Personal Care (10% of domestic revenue):

- Premium personal care maintained its growth trajectory through its digital-first portfolio, with digital-first brands reaching INR 6 bn in ARR during 3QFY25
- Beardo continued to perform ahead of management's expectations and is on track to report a double-digit EBITDA margin in FY25.
- Just Herbs and the personal care portfolio of Plix continued gaining traction with minimal cash burn. Plix has potential for INR 5 bn revenue in the medium term, given its mix of nutraceuticals, skin food, and hair food products.
- The "secret sauce" for taking digital brands offline involves maintaining price parity with online channels, selling at appropriate price points, limiting SKUs, and avoiding beauty advisors in the BPC category, as stores require an INR 75,000-100,000 sales throughput per store.
- **Profitability** : Digital brands at an aggregate basis are burning much lower cash in FY25 ; will deliver low to mid-single EBITDA margin in FY26 ; double digit margin in FY27

Outlook on Foods and Premium Personal Care:

 Targeting a 20-25% CAGR to double revenue by FY27, with Foods and Personal Care expected to contribute 25% of domestic business revenue, up from 21%.

Distribution:

- 3QFY25 marked the second quarter of Project SETU, a distribution expansion initiative. Marico aims to increase direct reach from 1 mn outlets in FY24 to 1.5 mn outlets by FY27.
- The project launched in six states (a mix of higher market share "Diversify" and lower market share "Transform" states) during 1Q and has now expanded to eleven states this quarter.
- Through FY25, Marico plans to scale up phase 1 and expand to more states, driving market share gains across urban and rural markets and enhancing assortment levels to enable diversification and premiumization.

Others : Alternate channels - 30% contribution ; CSD contributes - 6-7% of sales

International Business (26% of revenue, 31% of EBIT):

- The international business reported 16% constant currency growth momentum, with each key market delivering broad-based growth.
- International EBITDA margin improved 100 bps YoY to 27.1%

Bangladesh (40% of International business):

 Reported 20% constant currency growth on a subdued base, despite the operating environment being challenging.

Other Regions (60% of international revenue):

- MENA delivered 35% CCG, with strong performance in the Gulf region and Egypt.
- South Africa reported 17% constant currency growth due to robust growth in hair care and health care franchises.
- South East Asia had a soft quarter owing to sluggish consumption environment and geo-political issues in Myanmar.

Outlook:

• The international business will continue aiming for double-digit CCG on an aggregate level, focusing on geographical diversification.

Consolidated P&L

(INR mn)	FY23	FY24	FY25E	FY26E	FY27E
Net Revenues	97,640	96,530	1,05,833	1,16,563	1,27,316
Growth (%)	13.2	10.9	11.1	12.1	12.2
Material Expenses	53,510	47,480	51,991	57,034	61,882
Employee Expense	6,530	7,430	8,359	9,111	9,931
Other Expenses	19,500	21,360	23,693	25,718	27,920
EBITDA	18,100	20,260	21,790	24,701	27,583
EBITDA Growth (%)	7.7	11.9	7.6	13.4	11.7
EBITDA Margin (%)	18.5	21.0	20.6	21.2	21.7
Depreciation	1,550	1,580	1,678	1,858	2,038
EBIT	16,550	18,680	20,113	22,843	25,546
Other Income	1,440	1,420	1,562	1,718	1,890
Interest	560	730	584	584	584
PBT	17,430	19,370	21,091	23,977	26,852
Tax	4,210	4,350	5,062	5,755	6,444
Profit from minority/associates	(200)	(210)	(210)	(210)	(210)
RPAT	13,020	14,810	15,819	18,013	20,197
Adjustment	-	-	-	-	-
Adjusted PAT	13,020	14,810	15,819	18,013	20,197
APAT Growth (%)	6.3	13.7	6.8	13.9	12.1
Adjusted EPS	10.1	11.5	12.2	13.9	15.6
EPS Growth (%)	6.3	13.7	6.8	13.9	12.1

Source: Company, HSIE Research

Consolidated Balance Sheet


(INR mn)	FY23	FY24	FY25E	FY26E	FY27E
SOURCES OF FUNDS					
Share Capital - Equity	1,290	1,290	1,290	1,290	1,290
Reserves	36,700	37,030	40,194	43,796	47,836
Total Shareholders Funds	37,990	38,320	41,484	45,086	49,126
Minority Interest	1,570	3,370	3,580	3,790	4,000
Long Term Debt	20	-	-	-	-
Short Term Debt	4,730	3,830	3,830	3,830	3,830
Total Debt	4,750	3,830	3,830	3,830	3,830
Net Deferred Taxes	320	2,110	2,110	2,110	2,110
Other Non-current Liabilities & Provns	3,810	5,290	5,290	5,290	5,290
TOTAL SOURCES OF FUNDS	48,440	52,920	56,294	60,106	64,356
APPLICATION OF FUNDS					
Net Block	16,690	17,720	17,542	17,185	16,647
CWIP	670	440	440	440	440
Other Non Current Assets	12,500	15,390	15,390	15,390	15,390
Total Non-current Assets	29,860	33,550	33,372	33,015	32,477
Inventories	12,250	13,360	14,647	16,133	17,621
Debtors	10,150	10,690	8,699	9,581	10,464
Other Current Assets	2,400	3,910	3,910	3,910	3,910
Cash & Equivalents	13,340	12,020	17,799	21,359	25,536
Total Current Assets	38,140	39,980	45,055	50,983	57,531
Creditors	14,520	15,810	17,334	19,091	20,852
Other Current Liabilities & Provns	5,040	4,800	4,800	4,800	4,800
Total Current Liabilities	19,560	20,610	22,134	23,891	25,652
Net Current Assets	18,580	19,370	22,921	27,092	31,879
TOTAL APPLICATION OF FUNDS	48,440	52,920	56,294	60,106	64,356

Source: Company, HSIE Research

Consolidated Cash Flow					
(INR mn)	FY23	FY24	FY25E	FY26E	FY271
Reported PBT	17,430	19,370	21,091	23,977	26,852
Non-operating & EO Items	(580)	(510)	-	-	-
Interest Expenses	70	(40)	-	-	-
Depreciation	1,550	1,580	1,678	1,858	2,038
Working Capital Change	(590)	(2,260)	2,228	(610)	(611
Tax Paid	(3,690)	(3,780)	(5,062)	(5,755)	(6,444
OPERATING CASH FLOW (a)	14,190	14,360	19,934	19,471	21,834
Capex	(2,770)	(1,030)	(1,500)	(1,500)	(1,500
Free Cash Flow (FCF)	11,420	13,330	18,434	17,971	20,334
Investments	(2,200)	5,800	-	-	-
Non-operating Income	(3,680)	(3,010)	-	-	-
INVESTING CASH FLOW (b)	(8,650)	1,760	(1,500)	(1,500)	(1,500
Debt Issuance/(Repaid)	1,280	(910)	-	-	-
Interest Expenses	(940)	(1,170)	-	-	-
FCFE	5,200	18,200	18,434	17,971	20,334
Share Capital Issuance	90	340	-	-	-
Dividend	(5,820)	(12,290)	(12,655)	(14,410)	(16,158
Others	(210)	(1,390)	-	-	-
FINANCING CASH FLOW (c)	(5,600)	(15,420)	(12,655)	(14,410)	(16,158
NET CASH FLOW (a+b+c)	(60)	700	5,779	3,561	4,176
EO Items, Others	(630)	(490)	-	-	-
Closing Cash & Equivalents	2,070	2,280	8,059	11,619	15,796
Source: Company, HSIE Research					
Ratios					
KEY RATIOS	FY23	FY24	FY25E	FY26E	FY27
PROFITABILITY (%)					
GPM	45.2	50.8	50.9	51.1	51.4
EBITDA Margin	18.5	21.0	20.6	21.2	21.7
EBIT Margin	17.0	19.4	19.0	19.6	20.1
APAT Margin	13.3	15.3	14.9	15.5	15.9
RoE	36.4	38.8	39.6	41.6	42.9
RoIC (or Core RoCE)	68.9	56.1	54.4	64.8	72.6
RoCE	33.1	32.7	33.2	35.2	36.7
EFFICIENCY					
Tax Rate (%)	24.2	22.5	24.0	24.0	24.0
Fixed Asset Turnover (x)	8.2	7.3	7.2	7.2	7.2
Inventory (days)	45.8	50.5	50.5	50.5	50.5
Debtors (days)	37.9	40.4	30.0	30.0	30.0
Other Current Assets (days)	9.0	14.8	13.5	12.2	11.2
Payables (days)	54.3	59.8	59.8	59.8	59.8
Other Current Liab & Provns (days)	18.8	18.1	16.6	15.0	13.8
Cash Conversion Cycle (days)	19.6	27.8	17.7	17.9	18.2
Net D/E (x)	(0.2)	(0.2)	(0.3)	(0.4)	(0.4
Interest Coverage (x)	29.6	25.6	34.4	39.1	43.7
PER SHARE DATA (Rs)	27.0	25.0	54.4	57.1	45.7
EPS	10.1	11.5	12.2	13.9	15.
CEPS	11.3	12.7	13.5	15.4	17.2
Dividend	4.5	9.5	9.8	15.4	17.2
Book Value	4.3 29.4	29.6	32.1	34.9	38.0
VALUATION	27.4	27.0	52.1	54.2	56.0
	63.5	55.9	52.2	45.9	40.9
P/E(x)		55.8	52.3		
P/BV(x)	-	-	-	-	-
EV/EBITDA (x)	45.2	40.4	37.3	32.8	29.2
EV/Revenues (x)	8.4	8.5	7.7	6.9	6.3
OCF/EV (%)	1.7	1.8	2.5	2.4	2.7
FCF/EV (%)	1.4	1.6	2.3	2.2	2.5
	a .				
FCFE/Mkt Cap (%) Dividend Yield (%)	0.6 0.7	2.2 1.5	2.2 1.5	2.2 1.7	2.5 2.0



1 Yr Price Movement



Rating Criteria

BUY:>+15% return potentialADD:+5% to +15% return potentialREDUCE:-10% to +5% return potentialSELL:> 10% Downside return potential

Marico: 3QFY25 Results Review

Disclosure:

We, **Vishal Gutka**, **CA & Anuj D**, **BBA** authors and the names subscribed to this report, hereby certify that all of the views expressed in this research report accurately reflect our views about the subject issuer(s) or securities. SEBI conducted the inspection and based on their observations have issued advise/warning. The said observations have been complied with. We also certify that no part of our compensation was, is, or will be directly or indirectly related to the specific recommendation(s) or view(s) in this report.

Research Analyst or his/her relative or HDFC Securities Ltd. does not have any financial interest in the subject company. Also Research Analyst or his relative or HDFC Securities Ltd. or its Associate may have beneficial ownership of 1% or more in the subject company at the end of the month immediately preceding the date of publication of the Research Report. Further Research Analyst or his relative or HDFC Securities Ltd. or its associate does have/does not have any material conflict of interest.

Any holding in stock – No

HDFC Securities Limited (HSL) is a SEBI Registered Research Analyst having registration no. INH000002475.

Disclaimer:

This report has been prepared by HDFC Securities Ltd and is solely for information of the recipient only. The report must not be used as a singular basis of any investment decision. The views herein are of a general nature and do not consider the risk appetite or the particular circumstances of an individual investor; readers are requested to take professional advice before investing. Nothing in this document should be construed as investment advice. Each recipient of this document should make such investigations as they deem necessary to arrive at an independent evaluation of an investment in securities of the companies referred to in this document (including merits and risks) and should consult their own advisors to determine merits and risks of such investment. The information and opinions contained herein have been compiled or arrived at, based upon information obtained in good faith from sources believed to be reliable. Such information has not been independently verified and no guaranty, representation of warranty, express or implied, is made as to its accuracy, completeness or correctness. All such information and opinions are subject to change without notice. Descriptions of any company or companies or their securities mentioned herein are not intended to be complete. HSL is not obliged to update this report for such changes. HSL has the right to make changes and modifications at any time.

This report is not directed to, or intended for display, downloading, printing, reproducing or for distribution to or use by, any person or entity who is a citizen or resident or located in any locality, state, country or other jurisdiction where such distribution, publication, reproduction, availability or use would be contrary to law or regulation or what would subject HSL or its affiliates to any registration or licensing requirement within such jurisdiction.

If this report is inadvertently sent or has reached any person in such country, especially, United States of America, the same should be ignored and brought to the attention of the sender. This document may not be reproduced, distributed or published in whole or in part, directly or indirectly, for any purposes or in any manner.

Foreign currencies denominated securities, wherever mentioned, are subject to exchange rate fluctuations, which could have an adverse effect on their value or price, or the income derived from them. In addition, investors in securities such as ADRs, the values of which are influenced by foreign currencies effectively assume currency risk. It should not be considered to be taken as an offer to sell or a solicitation to buy any security.

This document is not, and should not, be construed as an offer or solicitation of an offer, to buy or sell any securities or other financial instruments. This report should not be construed as an invitation or solicitation to do business with HSL. HSL may from time to time solicit from, or perform broking, or other services for, any company mentioned in this mail and/or its attachments.

HSL and its affiliated company(ies), their directors and employees may; (a) from time to time, have a long or short position in, and buy or sell the securities of the company(ies) mentioned herein or (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies) or may have any other potential conflict of interests with respect to any recommendation and other related information and opinions.

HSL, its directors, analysts or employees do not take any responsibility, financial or otherwise, of the losses or the damages sustained due to the investments made or any action taken on basis of this report, including but not restricted to, fluctuation in the prices of shares and bonds, changes in the currency rates, diminution in the NAVs, reduction in the dividend or income, etc.

Marico: 3QFY25 Results Review

HSL and other group companies, its directors, associates, employees may have various positions in any of the stocks, securities and financial instruments dealt in the report, or may make sell or purchase or other deals in these securities from time to time or may deal in other securities of the companies / organizations described in this report. As regards the associates of HSL please refer the website.

HSL or its associates might have managed or co-managed public offering of securities for the subject company or might have been mandated by the subject company for any other assignment in the past twelve months.

HSL or its associates might have received any compensation from the companies mentioned in the report during the period preceding twelve months from the date of this report for services in respect of managing or co-managing public offerings, corporate finance, investment banking or merchant banking, brokerage services or other advisory service in a merger or specific transaction in the normal course of business.

HSL or its analysts did not receive any compensation or other benefits from the companies mentioned in the report or third party in connection with preparation of the research report. Accordingly, neither HSL nor Research Analysts have any material conflict of interest at the time of publication of this report. Compensation of our Research Analysts is not based on any specific merchant banking, investment banking or brokerage service transactions. HSL may have issued other reports that are inconsistent with and reach different conclusion from the information presented in this report.

Research entity has not been engaged in market making activity for the subject company. Research analyst has not served as an officer, director or employee of the subject company. We have not received any compensation/benefits from the subject company or third party in connection with the Research Report.

Please note that HDFC Securities has a proprietary trading desk. This desk maintains an arm's length distance with the Research team and all its activities are segregated from Research activities. The proprietary desk operates independently, potentially leading to investment decisions that may deviate from research views.

HDFC securities Limited, I Think Techno Campus, Building - B, "Alpha", Office Floor 8, Near Kanjurmarg Station, Opp. Crompton Greaves, Kanjurmarg (East), Mumbai 400 042 Phone: (022) 3075 3400 Fax: (022) 2496 5066

Compliance Officer: Murli V Karkera Email: complianceofficer@hdfcsec.com Phone: (022) 3045 3600

For grievance redressal contact Customer Care Team Email: customercare@hdfcsec.com Phone: (022) 3901 9400

HDFC Securities Limited, SEBI Reg. No.: NSE, BSE, MSEI, MCX: INZ000186937; AMFI Reg. No. ARN: 13549; PFRDA Reg. No. POP: 11092018; IRDA Corporate Agent License No.: CA0062; SEBI Research Analyst Reg. No.: INH000002475; SEBI Investment Adviser Reg. No.: INA000011538; CIN - U67120MH2000PLC152193

Investment in securities market are subject to market risks. Read all the related documents carefully before investing. Mutual Funds Investments are subject to market risk. Please read the offer and scheme related documents carefully before investing.

Registration granted by SEBI, membership of BASL (in case of IAs) and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.